Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Wed, 14.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta [ … ]
Technical analysis
To the publication
Wed, 14.12.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprieta [ … ]
Technical analysis
To the publication
Thu, 10.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 Heidelberg Pharma presents initial findings of the first in human study with ATAC® candidate HDP-101 Licensing partner Magenta presents initial data from Phase I/II study with ATAC® candidate MGTA- [ … ]
Technical analysis
To the publication
Thu, 10.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 Heidelberg Pharma presents initial findings of the first in human study with ATAC® candidate HDP-101 Licensing partner Magenta presents initial data from Phase I/II study with ATAC® candidate MGTA- [ … ]
Technical analysis
To the publication
Mon, 07.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study Ladenburg, Germany, 7 November 2022 – Heidelberg Pharma AG (FSE: HPHA) announced today that its licensing partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix) presented positive top-line data on its pivotal ZIRCON Phase III study with [ … ]
Technical analysis
To the publication
Mon, 07.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study Ladenburg, Germany, 7 November 2022 – Heidelberg Pharma AG (FSE: HPHA) announced today that its licensing partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix) presented positive top-line data on its pivotal ZIRCON Phase III study with [ … ]
Technical analysis
To the publication
Thu, 13.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022 First clinical trial with HDP-101 in multiple myeloma on track, third patient cohort started Significant progress achieved in partner projects and further ATAC® agreements signed with Chiome Bioscience and Takeda Rights issue with proceeds of approximately EUR 8 [ … ]
Technical analysis
To the publication
Thu, 13.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022 First clinical trial with HDP-101 in multiple myeloma on track, third patient cohort started Significant progress achieved in partner projects and further ATAC® agreements signed with Chiome Bioscience and Takeda Rights issue with proceeds of approximately EUR 8 [ … ]
Technical analysis
To the publication
Tue, 04.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma AG Announces Adjustment of Guidance Ladenburg, Germany, 4 October 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published on 24 March 2022. The license agreement with the strategic partner H [ … ]
Technical analysis
To the publication
Tue, 04.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma AG Announces Adjustment of Guidance Ladenburg, Germany, 4 October 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published on 24 March 2022. The license agreement with the strategic partner H [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.